$30.15
Value $1.8B
AGIO and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$30.15
Value $1.8B
$691.33
Value $257B
Agios Pharmaceuticals (AGIO) has a market value of $1.8B and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, AGIO moved -30.9% and TMO +19.9%. Dividend yield: AGIO none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AGIO$1.8B
TMO$257B
TMO is 145 times AGIO
Revenue, 12 months
AGIO$141M
TMO$47.4B
TMO is 336 times AGIO
Net income, 12 months
AGIO-$373M
TMO$7.1B
Operating margin
AGIO-297.7%
TMO17.9%
315.6 points apart
ROIC
AGIO-29.6%
TMO8.2%
37.8 points apart
P/E
AGIO–
TMO36.3
Dividend yield
AGIO0.0%
TMO0.3%
0.3 points apart
5-year return
AGIO-25.7%
TMO+10.9%
36.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AGIO-25.7%
TMO+10.9%
| Period | AGIOWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -30.9%Price -30.9% | +19.9%Price +19.5% |
| 3 years since November 16, 2023 | +35.6%+10.7% a yearPrice +35.6% | +47.7%+13.9% a yearPrice +46.3% |
| 5 years since November 15, 2021 | -25.7%-5.8% a yearPrice -25.7% | +10.9%+2.1% a yearPrice +9.3% |
| 10 years since November 16, 2016 | -51.3%-6.9% a yearPrice -51.3% | +375.7%+16.9% a yearPrice +362.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AGIOAgios PharmaceuticalsTMOThermo Fisher Scientific
| Price | $30.15 | $691.33 |
|---|---|---|
| Market value | $1.8B | $257B |
| Enterprise value (EV) | $860M | $292B |
| P/E | – | 36.3 |
| P/E, 5-year median | – | 32.7 |
| P/B | 1.8 | 4.7 |
| EV/EBIT | – | 34.5 |
| Free cash flow yield | – | 3.0% |
| Revenue, 12 months | $141M | $47.4B |
|---|---|---|
| Net income, 12 months | -$373M | $7.1B |
| Free cash flow, 12 months | -$336M | $7.6B |
| Earnings per share, 12 months | -$6.32 | $18.96 |
| Revenue growth, year on year | 48.0% | 3.9% |
| Revenue growth a year, past | – | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | 93.8% | – |
|---|---|---|
| Operating margin | -297.7% | 17.9% |
| Net margin | -264.8% | 14.9% |
| ROIC | -29.6% | 8.2% |
| ROE | -33.3% | 13.4% |
| Cash | $907M | $6.1B |
|---|---|---|
| Total debt | $27M | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($257B) is about 145.4 times Agios Pharmaceuticals ($1.8B), at today's prices.
Since November 16, 2016, AGIO's price moved -51.3% and TMO's +362.5%. With dividends: AGIO -51.3% (-6.9% a year), TMO +375.7% (+16.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Agios Pharmaceuticals and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
Over the last twelve months, the net margin was -264.8% for Agios Pharmaceuticals and 14.9% for Thermo Fisher Scientific, and the operating margin -297.7% and 17.9%. Revenue was $141M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.